Asset
ATOMOXETINE
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06566820 | phase3 | enrolling_by_invitation | 2024-07-03 | 2026-06-30 | Apnimed | Continuation Protocol for Obstructive Sleep Apnea (OSA) |
| NCT05101122 | phase1_2 | completed | 2021-10-19 | 2022-04-18 | Apnimed | Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED) |
| NCT04905979 | phase2 | completed | 2021-07-31 | 2023-01-31 | Apnimed | Trial of AD113 and Atomoxetine in OSA Patients With Hypertension |
FDA applications (0)
This company has no applications containing this asset.